OVID Therapeutics (OVID) - Biotech with strong nervesOVID Therapeutics is a biotech company focused on developing treatments for rare neurological and genetic disorders.
On the monthly chart, OVID has broken above a long-term descending trendline and is currently retesting it from above. The key support zone sits at 1.45, while the latest close at 1.67 confirms structure preservation. Volume expanded on the breakout and faded during the pullback, indicating a healthy retest. Monthly MACD remains above zero and shows bullish divergence, while RSI holds above 50, confirming a shift in market phase. Volume profile suggests a potential magnet zone above current prices if support continues to hold.
Fundamentally, the company remains unprofitable, which is typical for a development-stage biotech. Q4 2025 EPS is expected at −0.11, revenues are minimal, but debt levels are manageable and cash reserves provide operational runway.
This is a higher-timeframe positioning idea, where the market begins to reassess the asset after a prolonged downtrend. Biotech is never comfortable, but this is how monthly reversals usually start.
